What are the clinical trial results of Ocriplasmin?

Ocriplasmin (Ocriplasmin) is the first biological enzyme preparation approved for the treatment of symptomatic vitreomacular adhesion. Since its approval by the FDA, its efficacy and safety have been verified in multiple clinical trials around the world. The critical stage clinical trials of its development (such as the well-known overseas research MIVI-TRUST project) have laid the foundation for Ocriplasmin to become a representative drug for vitreous dissolution treatment.

In these clinical studies,Ocriplasmin showed significant improvement in macular traction via a single intravitreal injection. Most of the study subjects were patients with symptomatic VMA, some of whom had small macular holes. The results showed that compared with the placebo group, a significant proportion of patients who received Ocriplasmin injections experienced complete separation of the vitreous body and macula, and some patients' vision recovered within a few weeks to three months. This result confirms that Ocriplasmin can effectively relieve mechanical traction by dissolving vitreous and retinal junction proteins.

In terms of safety, a certain proportion of mild adverse reactions have also been observed in clinical trials, such as transient vision loss, flashing sensations, eye discomfort, and transient retinal function changes in electrophysiological testing. Most of these reactions are reversible and do not affect long-term efficacy. The researchers pointed out that the drug is more effective in patients with smaller macular holes and incomplete vitreous liquefaction, suggesting that patient selection is particularly critical in clinical application.

It is noteworthy thatOcriplasmin’s clinical data has promoted changes in ophthalmic treatment concepts. In the past, macular adhesion often relied on microsurgery, but the emergence of bioenzyme treatment provides a safer option for elderly patients and those who cannot tolerate surgery.

In summary, the clinical trial results of Oakplasmin provide strong evidence for its efficacy. Its success not only changed the treatment path for macular diseases, but also provided scientific basis for the development of more ophthalmic enzymatic treatment drugs in the future, indicating the direction of precision and stratification of ophthalmic drug treatment.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html